Kyverna Therapeutics 2024 CAR T-Cell Therapy Autoimmune Disease

Kyverna Therapeutics presents its cell therapy platform for autoimmune diseases, focusing on anti-CD19 CAR T-cell development. The company demonstrates proof-of-concept data in refractory systemic lupus erythematosus with sustained treatment-free remission and outlines its clinical development pipeline.